Does HER2 overexpression affect response to endocrine therapy in advanced cancer? Commentary

Nature Clinical Practice Oncology

Volumn 3, Issue 2, 2006, Pages 78-79

  Wardley, Andrew M ^a   Howell, Anthony ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Breast cancer; HER2; Hormonal therapy; Meta analysis; Response

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FULVESTRANT; LETROZOLE; TAMOXIFEN; TRASTUZUMAB;

ABSTRACT REPORT; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RISK; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; EMBASE; GENE OVEREXPRESSION; HUMAN; MEDLINE; META ANALYSIS; METASTASIS; PREVALENCE; PRIORITY JOURNAL; PUBLISHING; SHORT SURVEY; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE;

EID: 32844459740     PISSN: 17434254     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncponc0421     Document Type: Short Survey

References (4)

1. Lipton A et al. (2003) Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 21: 1967-1972
2. Ellis MJ et al. (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19: 3808-3816
3. Dowsett M et al. (2005) Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: Influence of hormonal status and HER-2 in breast cancer - a study from the IMPACT trialists. J Clin Oncol 23: 2477-2492
4. Hutcheson IR et al. (2003) Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res Treat 81: 81-93